Innergize

Dr. Siddhant Bhargava, Shalmali Kadu, and Mitansh Khurana are Season 4's most personally adversity-transformed founding trio. Each founder's health crisis directly informed InnerGize's mission. Dr. Siddhant was diagnosed with Lupus at age 20: his immune system attacked his own body, causing hair loss, skin discolouration, relentless pain, and debilitating steroid side effects. Later, he battled thyroid cancer. These experiences left him grappling with severe mental health challenges that no medication could adequately address. Before InnerGize, he founded Food Darzee, a diet food delivery service catering to celebrities including Alia Bhatt and Sara Ali Khan, demonstrating his ability to build and scale consumer health brands.

InnerGize Gen 1 is a wearable device that delivers gentle electrical impulses to the vagus nerve, the longest cranial nerve connecting the brain to major organs, activating the body's parasympathetic nervous system (the "rest and digest" system) to counteract the sympathetic nervous system's stress response (the "fight or flight" system). The science behind vagus nerve stimulation (VNS) is well-established: it has been FDA-approved in the US for treating epilepsy and depression since the 1990s. InnerGize's innovation is miniaturising this clinical technology into a consumer-grade wearable that anyone can use at home without a doctor's prescription, making neuromodulation therapy accessible to the 56 million Indians suffering from depression and 36 million suffering from anxiety disorders.

Amount Asked: ₹54 lakhs Equity Offered: 1.5% Implied Pre-Money Valuation: ₹36 crore

Dr. Siddhant, Shalmali, and Mitansh walked into Season 4 Episode 5 with the most emotionally powerful founding story of the early episodes. Siddhant opened with his Lupus diagnosis, the immune system attacking his own body, the hair loss, the pain, the cancer, and the mental health crisis that no medication could solve. Every Shark listened in silence. The product demonstration showed the InnerGize device being placed behind the ear, the app controlling the session, and the EEG readings tracking brain activity in real time. The clinical validation data was the pitch's strongest commercial asset: 1,100 plus users tested, 36% stress reduction in 3 sessions, backed by 100 plus physicians from India's most prestigious institutions (AIIMS, NIMHANS, KEM). The Sharks were divided. Kunal Bahl and Vineeta Singh opted out, citing the early stage and unclear product-market fit. But Ritesh immediately matched the founders' ask at ₹54 lakhs for 1.5%.

Kunal Bahl opted out, citing concerns about the brand being at too early a stage. Vineeta Singh exited for similar reasons: unclear product-market fit in a market where consumers have not yet been educated about vagus nerve stimulation. Ritesh Agarwal was the first to offer, matching the founders' exact ask of ₹54 lakhs for 1.5% equity (₹36 crore valuation). He saw the OYO-like scaling potential: deploying a health device across distributed locations (B2B mental health institutions initially, then D2C). Aman Gupta offered ₹54 lakhs for 2.5% equity (₹21.6 crore valuation), citing his background in wearable technology through boAt. zhar Iqubal saw immense potential in InnerGize's vision and joined the coalition, bringing Inshorts' digital content and young consumer engagement expertise to help educate India about vagus nerve stimulation.

Season 4's most intensely multi-round health-tech negotiation. Founders asked ₹54 lakhs for 1.5% (₹36 crore). Ritesh matched exactly. Aman offered ₹54 lakhs for 2.5% (₹21.6 crore). Aman, Ritesh, Azhar jointly offered ₹75 lakhs for 3%. Founders countered ₹1.08 crore for 3%. Aman rejected the discount condition on the next round. Final deal: ₹1 crore for 4.2% equity from three Sharks at ₹23.81 crore valuation. The founders received 85% more capital than their original ask while diluting only 2.7% more equity, a commercially strong negotiation outcome.

Dr. Siddhant Bhargava, Shalmali Kadu, and Mitansh Khurana accepted the three-Shark deal from Aman Gupta, Ritesh Agarwal, and Azhar Iqubal at ₹1 crore for 4.2% equity, valuing InnerGize at ₹23.81 crore. The deal brought India's most successful wearable technology brand builder (Aman, boAt), India's most experienced distributed-deployment scaler (Ritesh, OYO), and India's most digitally native young consumer content platform (Azhar, Inshorts) into India's first clinically validated mental health wearable, the most strategically complete three-Shark combination for a product that needs consumer education (Azhar), consumer hardware scaling (Aman), and institutional B2B deployment (Ritesh).

InnerGize has secured ₹4.5 crore in additional funding post-Shark Tank, bringing total pre-seed funding to ₹6.5 crore. The round was structured in two phases: the initial ₹2 crore from government schemes (Startup India Seed Fund, MeitY, NGIS, BIRAC) and the latest ₹4.5 crore from private investors. Notably, Aman Gupta revised his Shark Tank investment from ₹1 crore for 4.2% to ₹30 lakhs for 1.4% to accommodate other investors in the round, demonstrating the flexibility that characterises collaborative early-stage investment structures. The Shark Tank episode generated 1,300 plus pre-orders before the product even launched officially, validating massive consumer demand for a non-invasive stress relief device at ₹5,000. The official product launch was scheduled for April 2025. The B2B strategy involves partnering with mental health institutions on a pay-per-session model before transitioning to broader D2C sales.